Polyclone Bioservices has entered into an alliance with Innovendia Consulting of Germany. This will allow all the European biotech-platform and drug discovery companies to have easier access to assay design and validation services.
In addition the EU and national government funded consortia will benefit from the more immediate availability of Polyclone's unique combination of in vitro & in silico assay design and validation capabilities.
Innovendia is an entrepreneurial life science marketing, business development and strategy consulting firm with strong ties in the European bio-pharma community. It is located in Southern Germany in the biotech/pharma triangle consisting of South Germany, Switzerland, and France.
Dr Michael Steinwand, founder and managing director, Innovendia, said that the partnership would give us the opportunity to introduce a highly value and unique service to our existing clientele and will open the opportunity to let further users collaborate with Polyclone conveniently.
Polyclone Bioservices is a molecular biology and genomics company that synergistically combines in vitro and in silico approaches to address target and biomarker discovery & validation challenges. Polyclone is headquartered in Bangalore, India with operations in Europe and the US.
Our synergistic in-vitro and in silico services would enable European companies and research consortia to quickly and cost effectively design assays for various molecular biology & genomics applications while getting them validated on patient data and cell based assays in India, said Sanjay Bettadpura, chief business officer, Polyclone.
Polyclone and Innovendia will jointly present at the Indo-German workshop at Biotechnica, as well as in the bioinformatics session of the Innovation Forum at the same event.